紫杉醇脂质体与多西他赛联合顺铂治疗晚期肺鳞癌的疗效与安全性对比
Comparison of Paclitaxel Liposome Combined with Cisplatin and Docetaxel Combined with Cisplatin in the Treatment of Advanced Lung Squamous Cell Carcinoma
DOI: 10.12677/WJCR.2019.91006, PDF,   
作者: 张 莹：山东省胸科医院肺功能室，山东 济南；郭其森*：山东省肿瘤医院，山东 济南济南大学山东省医学科学院医学与生命科学学院，山东 济南；张初峰：山东省肿瘤医院呼吸肿瘤内科，山东 济南
关键词: 紫杉醇脂质体；多西他赛；顺铂；晚期肺鳞状细胞癌；临床有效率；不良反应；Paclitaxel Liposome； Docetaxel； Cisplatin； Advanced Lung Squamous Cell Carcinoma； Clinical Efficiency； Adverse Reactions
摘要: 目的：探讨注射用紫杉醇脂质体联合顺铂与多西他赛联合顺铂一线治疗晚期肺鳞癌的疗效和不良反应。方法：搜集并筛选2010年7月至2016年7月在山东省肿瘤医院确诊为晚期肺鳞癌并接受注射用紫杉醇脂质体联合顺铂(LP组)或多西他赛联合顺铂(DP组)一线化疗方案的病例，回顾分析两者的疗效和不良反应。结果：共纳入200例患者(各组100例)，LP组和DP组的有效率分别为39.0%和37.0% (P = 0.771)，疾病控制率分别为88.0%和85.0% (P = 0.415)，中位无进展生存期分别为5.6个月和5.2个月(P = 0.985)，中位总生存期分别为14.1个月和14.9个月(P = 0.0.713)。药物不良反应相比，LP组在骨髓抑制、胃肠道反应及过敏反应方面较轻(均P < 0.05)。结论：LP和DP两种方案治疗晚期肺鳞癌的疗效相似，但LP方案在骨髓抑制、胃肠道反应、过敏反应等方面的不良反应较轻。
Abstract: Objective: To explore the clinical efficacy and adverse reactions of paclitaxel liposome combined with cisplatin and docetaxel in combination with cisplatin in the treatment of patients with ad-vanced lung squamous cell carcinoma. Methods: To collect and select cases of patients with ad-vanced lung squamous cell carcinoma who were admitted to Shandong Provincial Cancer Hospital and from July 2010 to July 2016, and received paclitaxel liposome combined with cisplatin (LP group) or docetaxel in combination with cisplatin (DP group), and their efficacy and adverse reac-tions were compared. Results: A total of 200 patients (100 patients in each group) were included. The effective rates of the LP group and the DP group were 39.0% and 37.0% (P = 0.771), the disease control rates were 88.0% and 85.0% (P = 0.415), the median progression-free survival was 5.6 months and 5.2 months (P = 0.985) and the median overall survival was 14.1 months and 14.9 months (P = 0.713). Compared with the adverse reactions in the DP group, the LP group was lighter in myelosuppression, gastrointestinal reactions and allergic reaction (all P < 0.05). Conclusion: The efficacy of the LP regimen in the treatment of advanced lung squamous cell carcinoma is similar to that of the DP regimen, but the LP regimen has less adverse reactions in myelosuppression, gastrointestinal reactions and allergic reaction.
文章引用：张莹, 郭其森, 张初峰. 紫杉醇脂质体与多西他赛联合顺铂治疗晚期肺鳞癌的疗效与安全性对比[J]. 世界肿瘤研究, 2019, 9(1): 32-38. https://doi.org/10.12677/WJCR.2019.91006

参考文献

[1] 赫捷, 陈万青. 国家癌症中心和卫生部疾病预防与控制局. 中国癌症登记年报2012 [M]. 北京: 军事医学科学出版社, 2012.
[2] 曾晓梅, 李之曦, 侯梅. 紫杉醇脂质体单药与紫杉醇脂质体联合奥沙利铂一线治疗老年晚期非小细胞肺癌的随机对照研究[J]. 中国肺癌杂志, 2012, 15(2): 84-89.
[3] 杨静翔, 罗虎, 周向东. 紫杉醇脂质体对比吉西他滨联合顺铂一线治疗中晚期肺鳞癌的疗效评价[J]. 第三军医大学学报, 2014, 36(2): 140-143.
[4] 罗虎, 杨静翔, 宫亮, 等. 紫杉醇脂质体联合顺铂对比吉西他滨联合顺铂一线治疗伴有区域淋巴结转移的晚期非小细胞肺癌的临床研究[J]. 中国癌症杂志, 2013, 23(12): 995-1000.
[5] Joo, J.H., Song, S.Y., Kim, S.S., et al. (2015) Definitive Radiotherapy Alone over 60 Gy for Patients Unfit for Com-bined Treatment to Stage II-III Non-Small Cell Lung Cancer: Retrospective Analysis. Radiation Oncology, 10, 250.
[Google Scholar] [CrossRef] [PubMed]
[6] Eisenhauer, E.A., Therasse, P., Bogaerts, J., et al. (2009) New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1). European Journal of Cancer, 45, 228-247.
[Google Scholar] [CrossRef] [PubMed]
[7] 管忠震, 张力, 李龙芸, 等. 吉非替尼治疗局部晚期或转移性非小细胞肺癌在中国的临床研究[J]. 癌症, 2005, 24(8): 980-984.
[8] Cavaletti, G., Frigeni, B., Lanzani, F., et al. (2007) The Total Neuropathy Score as an Assessment Tool for Grading the Course of Chemotherapy-Induced Peripheral Neurotoxicity: Comparison with the National Cancer Institute-Common Toxicity Scale. Journal of the Peripheral Nervous System, 12, 210-215.
[Google Scholar] [CrossRef] [PubMed]
[9] 潘锋君, 田伟强, 吴小芬, 等. 多西他赛对比吉西他滨联合顺铂方案治疗非小细胞肺癌临床疗效[J]. 中国临床药理学杂志, 2014, 30(10): 949-951.
[10] 刘继柱, 徐文喜, 王斌. 多西他赛联合洛铂或顺铂治疗晚期非小细胞肺癌的临床研究[J]. 临床肺科杂志, 2014, 19(10): 1852-1853.
[11] Lu, B., Sun, L., Yan, X., Ai, Z., et al. (2015) Intratumoral Chemotherapy with Paclitaxel Liposome Combined with Systemic Chemotherapy: A New Method of Ne-oadjuvant Chemotherapy for Stage III Unresectable Non-Small Cell Lung Cancer. Medical Oncology, 32, 345.
[Google Scholar] [CrossRef] [PubMed]
[12] Huang, S.T., Wang, Y.P., Chen, Y.H., et al. (2018) Liposomal Paclitaxel In-duces Fewer Hematopoietic and Cardiovascular Complications than Bioequivalent Doses of Taxol. International Journal of Oncology, 1105-1117.
[Google Scholar] [CrossRef] [PubMed]
[13] 张丹华, 周恩相. 紫杉醇注射液、紫杉醇脂质体以及多西他赛治疗乳腺癌的疗效及安全性[J]. 中国癌症杂志, 2013, 23(12): 1014-1016.
[14] Ju, R.J., Cheng, L., Xiao, Y., et al. (2018) PTD Modified Paclitaxel Anti-Resistant Liposomes for Treatment of Drug-Resistant Non-Small Cell Lung Cancer. Journal of Liposome Research, 28, 236-248.
[Google Scholar] [CrossRef] [PubMed]
[15] Bernabeu, E., Cagel, M., Lagomarsino, E., et al. (2017) Paclitaxel: What Has Been Done and the Challenges Remain Ahead. International Journal of Pharmaceutics, 526, 474-495.
[Google Scholar] [CrossRef] [PubMed]
[16] Zhang, B., Xue, A., Zhang, C., et al. (2016) Bile Salt Liposomes for En-hanced Lymphatic Transport and Oral Bioavailability of Paclitaxel. Pharmazie, 71, 320-326.
[17] 李科, 刘洁琼. 奈达铂联合紫杉醇脂质体治疗晚期食管癌的临床效果及安全性[J]. 肿瘤研究与临床, 2016, 28(11): 748-751.
[18] Chen, Q., Zhang, Q.Z., Liu, J., et al. (2003) Multi-Center Prospective Randomized Trial on Paclitaxel Liposome and Traditional Taxol in the Treatment of Breast Cancer and Non-Small-Cell Lung Cancer. Chinese Journal of Oncology, 25, 190-192.

为你推荐